Waltzing transporters and 'the dance macabre' between humans and bacteria

被引：139

作者：

Lomovskaya, Olga

Zgurskaya, Helen I.

Totrov, Maxim

Watkins, William J.

机构：

[1] Mpex Pharmaceut Inc, San Diego, CA 92109 USA

[2] Univ Oklahoma, Dept Chem & Biochem, Norman, OK 73019 USA

[3] Molsoft LLC, La Jolla, CA 92037 USA

[4] Gilead Sci Inc, Foster City, CA 94404 USA

来源：

NATURE REVIEWS DRUG DISCOVERY | 2007年 / 6卷 / 01期

关键词：

D O I：

10.1038/nrd2200

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Multidrug-resistance efflux pumps - in particular those belonging to the resistance-nodulation-cell-division (RND) family of transporters, with their unusually high degree of substrate promiscuity - significantly restrict the effectiveness of antibacterial therapy. Recent years have heralded remarkable insights into the structure and mechanisms of these fascinating molecular machines. Here, we review recent advances in the field and describe various approaches used in combating efflux-mediated resistance.

引用

收藏

页码：56 / 65

页数：10

相关论文

共 104 条

[51] MexAB-OprM specific efflux pump inhibitors in Pseudomonas aeruginosa.: Part 3:: Optimization of potency in the pyridopyrimidine series through the application of a pharmacophore model [J].

Nakayama, K ;

Kawato, H ;

Watanabe, J ;

Ohtsuka, M ;

Yoshida, K ;

Yokomizo, Y ;

Sakamoto, A ;

Kuru, N ;

Ohta, T ;

Hoshino, K ;

Yoshida, K ;

Ishida, H ;

Cho, A ;

Palme, MH ;

Zhang, JZ ;

Lee, VJ ;

Watkins, WJ .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2004, 14 (02) :475-479

[52] MexAB-OprM specific efflux pump inhibitors in Pseudomonas aeruginosa.: Part 2:: Achieving activity in vivo through the use of alternative scaffolds [J].

Nakayama, K ;

Ishida, Y ;

Ohtsuka, M ;

Kawato, H ;

Yoshida, K ;

Yokomizo, Y ;

Ohta, T ;

Hoshino, K ;

Otani, T ;

Kurosaka, Y ;

Yoshida, K ;

Ishida, H ;

Lee, VJ ;

Renau, TE ;

Watkins, WJ .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2003, 13 (23) :4205-4208

[53] MexAB-OprM-specific efflux pump inhibitors in Pseudomonas aeruginosa.: Part 1:: Discovery and early strategies for lead optimization [J].

Nakayama, K ;

Ishida, Y ;

Ohtsuka, M ;

Kawato, H ;

Yoshida, K ;

Yokomizo, Y ;

Hosono, S ;

Ohta, T ;

Hoshino, K ;

Ishida, H ;

Yoshida, K ;

Renau, TE ;

Léger, R ;

Zhang, JZ ;

Lee, VJ ;

Watkins, WJ .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2003, 13 (23) :4201-4204

[54]

Neyfakh AA, 2001, J MOL MICROB BIOTECH, V3, P151

[55] Molecular basis of bacterial outer membrane permeability revisited [J].

Nikaido, H .

MICROBIOLOGY AND MOLECULAR BIOLOGY REVIEWS, 2003, 67 (04) :593-+

[56] Multidrug efflux pump AcrAB of Salmonella typhimurium excretes only those β-lactam antibiotics containing lipophilic side chains [J].

Nikaido, H ;

Basina, M ;

Nguyen, V ;

Rosenberg, EY .

JOURNAL OF BACTERIOLOGY, 1998, 180 (17) :4686-4692

[57] Preventing drug access to targets: cell surface permeability barriers and active efflux in bacteria [J].

Nikaido, H .

SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY, 2001, 12 (03) :215-223

[58] Ineffectiveness of topoisomerase mutations in mediating clinically significant fluoroquinolone resistance in Escherichia coli in the absence of the AcrAB efflux pump [J].

Oethinger, M ;

Kern, WV ;

Jellen-Ritter, AS ;

McMurry, LM ;

Levy, SB .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (01) :10-13

[59] Inhibitors of efflux pumps in Gram-negative bacteria [J].

Pagès, JM ;

Masi, M ;

Barbe, J .

TRENDS IN MOLECULAR MEDICINE, 2005, 11 (08) :382-389

[60]

Paulsen IT, 2001, J MOL MICROB BIOTECH, V3, P145

← 1 2 3 4 5 6 7 8 9 10 →